Influenza A virus conserved internal proteins (IAV internal proteins) (IAV internal proteins)

Influenza A virus conserved internal proteins, including the nucleoprotein (NP), matrix proteins (M1 and M2), and the heterotrimeric polymerase complex (PA, PB1, and PB2), are essential components of the viral architecture and replication machinery [UniProt P03466, P03485, P06821]. Unlike the surface glycoproteins hemagglutinin (HA) and neuraminidase (NA), which are subject to intense selective pressure and rapid antigenic drift, these internal proteins remain highly conserved across diverse influenza strains and subtypes. This conservation makes them ideal targets for 'universal' influenza vaccines designed to provide heterosubtypic immunity and for broad-spectrum antivirals that maintain efficacy against emerging pandemic threats. In clinical practice, the polymerase complex is targeted by inhibitors like baloxavir marboxil, which blocks the cap-dependent endonuclease activity of the PA subunit, and favipiravir, which acts as a chain terminator during RNA synthesis. The M2 protein, a proton-selective ion channel, was historically targeted by adamantanes, though widespread resistance has largely rendered these drugs obsolete for seasonal influenza. Current therapeutic strategies also focus on the nucleoprotein (NP) and matrix protein 1 (M1) as primary targets for T-cell mediated vaccines, aiming to induce robust cellular immune responses that can reduce disease severity and accelerate viral clearance regardless of the virus's surface subtype [Grant et al., 2013, J Virol; Hayden et al., 2018, NEJM].

Other names

Conserved influenza antigensInfluenza core proteinsIAV internal antigensConserved viral proteins

Inhibition of the viral polymerase complex (specifically PA endonuclease, PB1, and PB2 subunits) to prevent RNA synthesis; blockade of the M2 proton channel to inhibit viral uncoating; and induction of cross-reactive CD8+ T-cell responses against conserved epitopes in NP and M1 to clear infected cells [Hayden et al., 2018, NEJM; Grant et al., 2013, J Virol].